Publications

Preclinical
Molecular Cancer Therapeutics
February 14, 2024
Design and evaluation of ZD06519, a novel camptothecin payload for antibody drug conjugates
Petersen et al.
Preclinical
PepTalk
January 17, 2024
Engineering a Pure and Stable Heterodimeric IgA for the Development of Multispecific Therapeutics
Meghan Verstraete
Preclinical
SITC
November 4, 2023
TriTCE Co-Stim: A novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the therapeutic window for treatment of poorly infiltrated tumors
Newhook et al.
Preclinical
SITC
November 4, 2023
TriTCE CPI: a novel trispecific T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors
Verstraete et al.
Preclinical
World ADC San Diego
October 18, 2023
ZW220 – A Potential First-in-Class TOPO1i ADC for the Treatment of NaPi2b-Expressing Solid Tumors​ 
Andrea Hernández Rojas
Preclinical
World ADC San Diego
October 16, 2023
ZW251 – A novel glypican-3 targeting ADC bearing a topoisomerase I inhibitor payload
Laurence Madera
Preclinical
AACR-EORTC-NCI
October 12, 2023
Refining our understanding of ADCs: Drug development insights from 40 years of data
Raffaele Colombo
Preclinical
Festival of Biologics
October 10, 2023
TOPO1i ADC Platform From Concept to Pipeline Application
Mark Petersen
Preclinical
World Bispecific Summit
October 2, 2023
Engineering Trispecific T-cell Engagers to Address Biological Challenges in the Treatment of Solid Tumors
Nina Weisser
Preclinical
Journal of Medicinal Chemistry
June 12, 2023
Structure–Activity Relationships of Bis-Intercalating Peptides and Their Application as Antibody–Drug Conjugate Payloads
Petersen et al.
Preclinical
Bioorganic & Medicinal Chemistry Letters
June 2, 2023
Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: application as payloads for immunostimulatory antibody drug-conjugates
Brant et al.
Preclinical
PEGS
May 15 - May 19, 2023
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)
Garnett et al.